Fresh insights on how to realize success with members taking a GLP-1 for Type 2 Diabetes

Dario, a leader in the global digital health market, has unveiled two new studies at the 84th Annual American Diabetes Association (ADA) Scientific Sessions in Orlando. These studies showcase the impact of Dario’s cardiometabolic solution, particularly for users tracking GLP-1 medications. 

Enhancing GLP-1 Efficacy with Healthy Behaviors 

Adopting and maintaining healthy behaviors while taking a GLP-1 medication is essential for the drug’s effectiveness. Dario’s innovative cardiometabolic solution, with its integrated tools for GLP-1 medications, supports users in achieving sustainable behavior changes. These changes not only enhance the efficacy of the medication but also help users maintain healthy outcomes after they stop taking the drug. 

“This new research shows there is tremendous value in giving people a digital health solution designed for behavior change alongside GLP-1 medications. We are excited to see this early data reinforce what we have seen in the general member population: our highly personalized approach to behavior change works,” said Yifat Hershcovitz, PhD., Vice President of Clinical and Scientific Affairs at Dario. 

“Standards of care for cardiometabolic health are evolving thanks to new GLP-1 medications, but research, including Dario’s newest study, continues to demonstrate the importance of effective behavior change. These medications require the meaningful and sustainable change that Dario consistently delivers for our members and our clients to support full realization of the value of these drugs,” added Omar Manejwala, M.D., Chief Medical Officer. 

Long-Term Healthy Behavior Adoption with Dario 

To explore how Dario supports members taking a GLP-1, a retrospective analysis was conducted. The study focused on members managing Type 2 diabetes or prediabetes while taking either Metformin, a standard diabetes medication, or a GLP-1. Both groups were monitored over 12 months, tracking blood glucose levels and lifestyle activities such as diet and exercise. Members also used Dario’s Medication Cabinet feature to log medication reminders and report adherence. 

Key findings from the study include: 

Sustained Healthy Behaviors: Both groups showed significant improvement in adopting healthy behaviors over the 12-month period. This was evidenced by increased logging of meals and physical activities, which began in the first three months and continued throughout the year. 

Enhanced Outcomes with GLP-1: Members using a GLP-1 experienced a significant reduction in blood glucose levels within the first five months, maintaining these improvements throughout the year. 

Increased Engagement: GLP-1 users demonstrated a notable increase in the number of monthly weight measurements over the 12 months, highlighting sustained engagement with healthy lifestyle tracking. 

These studies underscore the effectiveness of Dario’s digital health solution in fostering long-term, sustainable behavior change, which is crucial for maximizing the benefits of GLP-1 medications and improving overall health outcomes for users.